Our Firm continues to hear from Lipitor patients on a regular basis, all of whom allegedly developed new-onset Type 2 diabetes due to their use of this cholesterol lowering statin. We are pleased to see federal Lipitor lawsuits moving forward,
New York, New York (PRWEB) October 31, 2014
The federal Lipitor diabetes (http://www.lipitorlawsuitcenter.com/lipitor-diabetes/) litigation now underway in U.S. District Court, District of South Carolina is continuing to move forward, Bernstein Liebhard LLP reports. According to an Order issued last month, the Court has dismissed 20 Lipitor lawsuits from the proceeding because Plaintiffs’ Fact Sheets for those cases were not completed by the specified deadline. However, the Order did note that at least 13 of the affected plaintiffs were planning to seek dismissal of their claims, but had not yet filed motions with the Court. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm continues to hear from Lipitor patients on a regular basis, all of whom allegedly developed new-onset Type 2 diabetes due to their use of this cholesterol lowering statin. We are pleased to see federal Lipitor lawsuits moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Despite these dismissals, court records indicate that more than 1,300 Lipitor lawsuits involving diabetes allegations are still pending in the District of South Carolina. Plaintiffs in these claims allege that Pfizer Inc. was aware that the statin could increase a patient’s risk for developing Type 2 diabetes, but concealed this information from patients and doctors. They further allege that information added to the Lipitor label in 2012 to address its association with diabetes was inadequate, and still does not adequately warn of this risk.
The Lipitor diabetes litigation has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered the manufacturers of statin drugs to include information on their labels regarding a possible association between their use and Type 2 diabetes. The FDA acted after a study published in JAMA: Internal Medicine indicated that women using the medications may be at an increased risk of developing the disease.*
Individuals who allegedly developed new-onset Type 2 diabetes due to their use of Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com